MMP9‐Responsive Graphene Oxide Quantum Dot‐Based Nano‐in‐Micro Drug Delivery System for Combinatorial Therapy of Choroidal Neovascularization
Small · 2023
DOI: 10.1002/smll.202207335 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2023. Verfasst von Keke Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Advanced Materials for Nano-Bio Applications, School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, …. Hauptthemen laut MEDLINE: Quantum Dots, Choroidal Neovascularization. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Age‐related macular degeneration (AMD), especially wet AMD with choroidal neovascularization (CNV), commonly causes blindness in older patients and disruption of the choroid followed by second‐wave injuries, including chronic inflammation, oxidative stress, and excessive matrix metalloproteinase 9 (MMP9) expression. Increased macrophage infiltrate in parallel with microglial activation and MMP9 overexpression on CNV lesions is shown to contribute to the inflammatory process and then enhance pathological ocular angiogenesis. Graphene oxide quantum dots (GOQDs), as natural antioxidants, exert anti‐inflammatory effects and minocycline is a specific macrophage/microglial inhibitor that can suppress both macrophage/microglial activation and MMP9 activity. Herein, an MMP9‐responsive GOQD‐based minocycline‐loaded nano‐in‐micro drug delivery system (C18PGM) is developed by chemically bonding GOQDs to an octadecyl‐modified peptide sequence (C18‐GVFHQTVS, C18P) that can be specifically cleaved by MMP9. Using a laser‐induced CNV mouse model, the prepared C18PGM shows significant MMP9 inhibitory activity and anti‐inflammatory action followed by antiangiogenic effects. Moreover, C18PGM combined with antivascular endothelial growth factor antibody bevacizumab markedly increases the antiangiogenesis effect by interfering with the “inflammation‐MMP9‐angiogenesis” cascade. The prepared C18PGM shows a good safety profile and no obvious ophthalmic or systemic side effects. The results taken together suggest that C18PGM is an effective and novel strategy for combinatorial therapy of CNV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Advanced Materials for Nano-Bio Applications, School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325027, P. R. China.
- Department of ophthalmology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei, 435000, P. R. China.
- Department of Ophthalmology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu, Sichuan, 610031, P. R. China.
ORCID-Profile: Juan Guo
Förderung
- Natural Science Foundation of Sichuan Province
Zitieren
APA
Huang, K., Liu, X., Lv, Z., Zhang, D., Zhou, Y., Lin, Z., & Guo, J. (2023). MMP9‐Responsive Graphene Oxide Quantum Dot‐Based Nano‐in‐Micro Drug Delivery System for Combinatorial Therapy of Choroidal Neovascularization. Small. https://doi.org/10.1002/smll.202207335
Vancouver
Huang K, Liu X, Lv Z, Zhang D, Zhou Y, Lin Z, et al. MMP9‐Responsive Graphene Oxide Quantum Dot‐Based Nano‐in‐Micro Drug Delivery System for Combinatorial Therapy of Choroidal Neovascularization. Small. 2023. doi:10.1002/smll.202207335
BibTeX
@article{Huang2023,
author = {Huang, Keke and Liu, Xin and Lv, Ziru and Zhang, Di and Zhou, Yuling and Lin, Zhiqing and Guo, Juan},
title = {MMP9‐Responsive Graphene Oxide Quantum Dot‐Based Nano‐in‐Micro Drug Delivery System for Combinatorial Therapy of Choroidal Neovascularization},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202207335}
}
EUVIMED